FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:1930-1931 May 5, 2005 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

To the Editor: Teriparatide represents a new class of therapeutic options for osteoporosis. Since it is a parathyroid hormone derivative, many practitioners are concerned about hypercalcemia, which is seen in hyperparathyroidism, and about how best to monitor their patients receiving this therapy. A major study of this compound in the Journal¹ stated that transient and chronic hypercalcemia were rare, that changes in vitamin D metabolism occurred, and that manipulation of mineral or drug doses helped lower serum calcium levels. Published data are not available, to my knowledge, however.

In my initial use of this drug, persistent hypercalcemia (i.e., serum calcium . . . [Full Text of this Article]

Related Letters:

Teriparatide, Osteoporosis, Calcium, and Vitamin D
Vieth R., Cole D. E.C., Krege J. H., Donley D. W., Marcus R., Licata A. A.
Extract | Full Text | PDF  
N Engl J Med 2005; 353:634-635, Aug 11, 2005. Correspondence

This article has been cited by other articles:

• Vieth, R., Cole, D. E.C., Krege, J. H., Donley, D. W., Marcus, R., Licata, A. A. (2005). Teriparatide, Osteoporosis, Calcium, and Vitamin D. NEJM 353: 634-635 [Full Text]